

Article

Not peer-reviewed version

Is It Necessary to Adapt the Training According to the Menstrual Cycle? Influence of Contraception and Physical Fitness Variables

[Paula Recacha-Ponce](#) , [Eladio Collado-Boira](#) ^{*} , Pilar Suarez-Alcazar , Macarena Montesinos-Ruiz , [Carlos Hernando-Domingo](#)

Posted Date: 17 July 2023

doi: 10.20944/preprints202307.1129.v1

Keywords: menstrual cycle, contraceptive cycling, VO2max, physical fitness, sensory threshold.



Preprints.org is a free multidiscipline platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Article

Is It Necessary to Adapt the Training According to the Menstrual Cycle? Influence of Contraception and Physical Fitness Variables.

Paula Recacha-Ponce ¹, Eladio Collado-Boira ^{2,*}, Pilar Suarez-Alcazar ³,
Macarena Montesinos-Ruiz ⁴ and Carlos Hernando-Domingo ⁵

¹ Faculty of Health Sciences. Jaime I University, 12071 Castello de la Plana, Spain; recacha@uji.es.
ORCID: 0000-0003-2092-8212

² Faculty of Health Sciences. Jaime I University, 12071 Castello de la Plana, Spain; colladoe@uji.es
ORCID: 0000-0001-8062-4152

³ Faculty of Health Sciences. Jaime I University, 12071 Castello de la Plana, Spain; malcazar@uji.es
ORCID: 0000-0002-5556-6007

⁴ Faculty of Health Sciences. Jaime I University, 12071 Castello de la Plana, Spain;
macarenamontesinosruiz@gmail.com ORCID: 0009-0000-6866-7109

⁵ Faculty of Health Sciences. Jaime I University, 12071 Castello de la Plana, Spain; hernando@uji.es
ORCID: 0000-0001-7182-4785

* Correspondence: colladoe@uji.es

Abstract: (1) Background: The influence of the menstrual cycle on physical fitness in athletes is controversial in the scientific literature. There is a marked fluctuation of sex hormones at three key points of the menstrual cycle, where estrogen and progesterone vary significantly. Hormonal contraception induces hormonal levels different from the natural menstrual cycle, requiring specific study in relation to physical fitness. (2) Method: Women aged 18 to 40 years with regular natural menstrual cycles and women using hormonal contraception were recruited, creating two study groups. All participants needed to be athletes classified as level II-III according to the classification by McKay et al (2021), based on training volume/physical activity metrics, among other variables. To assess their physical fitness, Cardiorespiratory Fitness (measured by $\dot{V}O_2\text{max}$), high-speed strength, hand grip strength, and flexibility were evaluated. Blood samples were taken to determine the menstrual cycle phase through analysis of sex hormone levels. Additionally, urine tests for ovulation detection were performed for the natural menstrual cycle group. Neurosensory stimulation tests were incorporated to measure sensory threshold and pain threshold in each phase. Body composition in each phase and its relationship with the other variables were also taken into account. (3) Results: Athletes in the natural cycling group showed differences in $\dot{V}O_2\text{max}$ ($\text{mL}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$) (phase I = 41.75 vs phase II = 43.85 and ($p=0.004$) and phase I vs phase III = 43.25 $\text{mL}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$ ($p=0.043$)), as well as in body weight (phase I = 63.23 vs. phase III = 62.48 kg; $p=0.006$), first pain threshold (phase I = 1.34 vs. phase II = 1.69 ($p=0.027$) and phase III = 1.59 mA ($p=0.011$)), and sensitive threshold (phase I = 0.64 vs. phase II = 0.76 mA ($p=0.017$)). The pain threshold was found to be an important covariate in relation to $\dot{V}O_2\text{max}$, explaining 31.9% of the variance in phase I ($p=0.006$). These findings were not observed between the two phases of contraceptive cycling. (4) Conclusion: The natural menstrual cycle will cause significant changes in the physical fitness of athletes. The use of hormonal contraception is not innocuous. Women with natural cycles show a decrease in cardiorespiratory fitness in phases II and III, which is a factor to be considered in relation to training level and workload.

Keywords: menstrual cycle; contraceptive cycling; $\dot{V}O_2\text{max}$; physical fitness; sensory threshold

1. Introduction

Female sex hormones are the main regulators of fertility and reproduction with secretion that varies throughout the ovarian cycle, having numerous physiological effects of a systemic nature (1). Given the diverse effects of estrogen and progesterone, it would not be surprising that the timing of the menstrual cycle (MC) could influence the physical fitness of female athletes. Aspects such as cardiorespiratory capacity, high-speed strength, handgrip strength, and flexibility (2) could be modified due to the hormonal fluctuations associated with the menstrual cycle. However, several meta-analyses have concluded that studies with higher methodological quality are needed to determine the effects of sex hormones on physical fitness (3,4). Even if these changes were minimal, they would be of importance in female athletes, where the goal is to achieve the best performance in competitive events (5). For this reason, symptoms associated with the menstrual cycle (bloating, pain, irritability, etc.) (6) also become relevant as they may, to a greater or lesser extent, affect physical fitness.

There are studies that confirm that hormones related to the menstrual cycle influence cardiovascular, respiratory, neuromuscular, neurocognitive and metabolic parameters, and as a consequence, physical fitness (7–10). Conversely, there are also studies in the literature that contradict the previously mentioned findings, concluding that the menstrual cycle does not influence physical fitness (11–13). This discrepancy could be attributed to the hormonal patterns of natural menstrual cycles. It is possible that results have been generalized among women with natural ovulatory cycles and women with deficient luteal phases, where progesterone levels are not sufficient to trigger ovulation (14), leading to an error as these women have different hormonal patterns. In physically active women, this becomes particularly important as they have a higher risk of experiencing deficient luteal phases (15), with reported rates of up to 30% among women engaging in exercise (16). Therefore, it is crucial to study this specific profile without generalizing the results to women who do have physiological luteal phases. Determining sex hormones (estrogen and progesterone) in blood is recommended as the gold standard for determining menstrual cycle phases and differentiating between ovulatory cycles and cycles with deficient luteal phases (14,17). The measurement of free androgens index (FAI) is also important. FAI measures total testosterone and sex hormone-binding globulin (SHBG). FAI measurement helps determine whether a cycle is ovulatory or not, as it is elevated in anovulatory cycles (16,18). However, testosterone levels alone are similar between ovulatory cycles (19).

Furthermore, another important profile to consider is hormonal contraception, as it differs from the natural menstrual cycle and needs to be specifically analyzed (20–23). Indirect evidence that the menstrual cycle could influence female athletes is that many of them use hormonal contraception to manipulate their cycles and control when they have menstruation (24). Additionally, there are studies suggesting that hormonal contraceptives may have detrimental effects on $\dot{V}O_{2max}$ (21,22).

The aim of this study was to investigate whether the menstrual cycle, both natural menstrual cycling (MC) and contraceptive MC, influences variables related to physical fitness, body composition, pain, and sensitivity.

2. Materials and Methods

Experimental design.

This is a study with cross-sectional prospective cohort design. Two study groups were created: natural cycling and contraceptive cycling, and assessments were conducted targeting the physical fitness based on the phase of the menstrual cycle in which the athlete was.

Table 1 shows a summary of the protocol for the tests performed. All the tests described below were performed three times for the natural cycling group, and twice for the contraceptive cycling group, depending on the phase of the participant's MC. The timing of the assessments was based on the phases of the menstrual cycle where the greatest hormonal fluctuations occur (17,23). Each of these visits was adjusted to the standardized test protocol, which included: verification of the athlete's health, measurement of body composition, measurement of the pain and sensory threshold,

extraction of blood sample, standardized warm-up, and performance of the 8 tests to evaluate physical performance (tests to measure the level of flexibility, high-speed strength, handgrip strength and cardiorespiratory fitness). The procedures carried out were identical among all participants and at all visits. All athletes were instructed and familiarized with the operation of all tests prior to valid attempts. It should be noted that the participants are trained women and knowledgeable about all these tests in their usual training. During all tests, participants received standardized verbal instructions from the research team.

Table 1. Summary of the research protocol, based on a menstrual cycle of 28 days duration [12].

Days of the standard menstrual cycle	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28
Phases of the natural cycle	Phase I					Phase II					Phase III																	
Phases of the contraceptive cycle																		Active HC								Inactive HC		
Interview	x											x						y			x						y	
Body composition	x											x						y			x						y	
Sensory threshold	x											x						y			x						y	
Pain threshold	x											x						y			x						y	
Blood collection	x											x						y			x						y	
Warm up	x											x						y			x						y	
Sit and Reach	x											x						y			x						y	
Hand grip	x											x						y			x						y	
SJ with 50% body weight	x											x						y			x						y	
SJ	x											x						y			x						y	
CMJ	x											x						y			x						y	
Abalakov jump	x											x						y			x						y	
DJ from 40 cms	x											x						y			x						y	
Ovulation test (Natural MC)	From day 8 of the cycle to positive test																											

Overview of the study protocol describing days of assessments and the outcomes measured in relation to a standard 28-day menstrual cycle. The highlighted days correspond to the range of cycle days where measurements were taken individually for each woman. The testing period included three visits, each following a standardized testing protocol as outlined: a brief medical history before proceeding with the rest of the tests, bioimpedance analysis, measurement of sensory threshold and first pain threshold, blood extraction, standardized warm-up, and a battery of physical tests: Sit and Reach, Hand grip, Squat Jump with 50% body weight, Squat Jump, Counter Movement Jump, Abalakov jump, and Drop jump from a height of 40 cm. A urinary ovulation test was performed each morning from day 8 of the MC until a positive test result was observed. SJ: Squat jump; CMJ: Counter Movement Jump; DJ: Drop jump. x = tests carried out in the natural MC group; y = tests carried out in the contraceptive MC group.

Determination of the phases of the natural MC.

The hormonal fluctuations are most noticeable in three key phases of the natural MC (17). Thus, following these recommendations of de Jonge XJ et al (2019), in this study, the following phases were taken into account, listed according to the order of appearance in a eumenorrheic MC:

Phase I: Where estrogen and progesterone have low concentrations. In this research this phase was considered from the first day of bleeding to day 5 (17,23). The assessment of phase I was conducted as soon as possible from the first day of bleeding, with the cutoff for this first assessment being day 5 of the menstrual cycle.

Phase II: Detected by a positive urinary ovulation kit (Luteinizing Hormone (LH) screening). It is characterized by a marked increase in estrogen, as well as progesterone (compared to phase I). This research considered this phase from positive urinary ovulation kit, until 48 hours after detection (23).

Phase III: Both estrogen and progesterone have higher levels than in the previous phases. Progesterone had to be greater than 16 nmol·L⁻¹(17). This study considered this phase 7 days after detecting the positive urinary ovulation (17,23)

The verification of these phases was determined taking into account the following recommendations from the literature:

Menstrual cycle mapping: Women communicated with the research team on the first day of their menstruation, determining that day as day 1 of the cycle.

Urinary LH measurement: participants performed the ovulation detection test from day 8 of the cycle until they saw a positive result on the urine strip (Ovulation test, Acofar, Madrid, Spain). It was requested that it should be carried out first thing in the morning, and an appointment was scheduled as soon as possible to carry out the tests. At the first visit, women in the natural MC group, were shown how to use the urinary LH detection strips. In women in whom no positive result was detected, the tests were repeated in the next cycle. A negative test result on two consecutive occasions led to the exclusion of the athlete from the study. The result was verified by photographic evidence (17,23).

Serum hormone analysis: estrogen and progesterone levels were determined. In addition, LH and follicle stimulating hormone (FSH) were also measured in each phase, in order to detect possible pathologies such as polycystic ovary syndrome (PCOS). To determine whether ovulation had occurred or not, a minimum limit of $16 \text{ nmol}\cdot\text{L}^{-1}$ of serum progesterone was stated (17,23), determined between 7-9 days after the positive ovulation was detected in the urine. Subsequently, based on the levels of progesterone obtained in the analysis, all those who showed serum levels of progesterone greater than $16 \text{ nmol}\cdot\text{L}^{-1}$ were included in the group of women with natural ovulatory cycles. A lower result was grounds for exclusion from the analysis (17,23).

In this study, following the outlined guidelines, the assessments for women with a natural menstrual cycling were conducted at the following intervals: the first visit (between day 1 and 5 of the cycle), the second visit (between day 12 and day 16), and the third visit (between day 19 and day 24 of the cycle).

Phases of the contraceptive MC

In the case of women with a contraceptive cycle, they were analyzed twice. The moment of active contraceptive use, where exogenous hormone levels are elevated (between days 18-21 of the cycle), was analyzed as well as the moment of inactive contraceptive use, where endogenous hormone levels are elevated (between days 26-28 of the cycle). In monophasic cycles, the exogenous concentration of ethinyl estradiol doubles from day one of active contraceptive use until day 21 (26,27). The progestin concentration triples from day 1 to days 8-11 and remains stable thereafter until day 21(27,28). All types of hormonal contraception (HC) used were monophasic with low doses of ethinyl estradiol ($< 0.03 \text{ mg}$) and second or third generation progestogens (levonogestrel, etonogestrel, drospirenona) (29).

All of the women started the study in the final of inactive phase of HC (between days 26-28 of the cycle). The second and final visit took was during the late stage of the active phase of the HC (between days 18-21 of the cycle).

Study variables

Hormonal variables: progesterone ($\text{nmol}\cdot\text{L}^{-1}$), estrogen (pmol/L), FSH (mIU/mL), LH (mIU/mL), total testosterone (nmol/L), SHBG (nmol/L), urinary LH (only in natural cycle), progesterone/estrogen ratio (P/E ratio), and FAI.

Variables related to physical fitness:

- Cardiorespiratory fitness: $\dot{V} \text{O}_2\text{max}$ ($\text{mL}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$) (indirectly calculated using the Course Navette test formula, explained later), and total meters achieved in the Course Navette test (m).
- High-speed strength: squat jump 50% additional body weight (cm), squat jump (cm), counter movement jump (cm), abalakov jump (cm), and drop jump from 40 cm (cm).
- Hand grip strength: dominant hand grip (kg).
- Flexibility: Seat and Reach test (cm).

Variables related to body composition: height, body mass (kg), total body water (L), body fat percentage (%), skeletal muscle mass (kg), BMI ($\text{kg}\cdot\text{m}^{-2}$).

Variables related to sensitivity and pain: sensory threshold (mA), first pain threshold (mA).

Participants

Women with naturally menstrual cycling and women with contraceptive menstrual cycling were recruited. All women were classified within level II and level III of the classification framework by McKay et al. (30) based on training volume and performance metrics. The participants were recruited through social networks with the dissemination of the research. Women interested in participating were informed and sent a questionnaire through the Qualtrics® platform, from which participants were selected based on the established inclusion and exclusion criteria.

The inclusion criteria for both groups were as follow: 1) healthy women, 2) age between 18 to 40 years, 3) body mass index (BMI) ≥ 18.5, 4) being classified within level II and level III of the classification framework by McKay et al. 5) do not consume alcohol or tobacco.

Specifically for the natural MC group: women with regular menstrual cycles lasting between 25 and 35 days for the past 6 months.

Specifically for the contraceptive MC group: women who have been using hormonal contraception for at least 6 months, with monophasic cycles, and low-dose ethinyl estradiol (<0.03) and second or third-generation progestogens.

The sociodemographic characteristics are defined in Table 2.

Table 2. Participant characteristics.

Measurement	Natural MC (n=20)	Contraceptive MC (n=14)	P value
Age (yr)	26.55 ± 5.880	26.86 ± 5.187	0.769
Height (cm)	165.21 ± 6.529	162.11 ± 5.088	0.231
BMI (kg·m ⁻²)	23.06 ± 2.419	22.79 ± 3.087	0.545
Age at first menstruation (yr)	12.15 ± 1.137	12. 62 ± 1.557	0.501
Duration of cycles	27.90 ± 2.732	27. 23 ± 1.739	0.598
Duration of bleedings	4.41 ± 0.795	3. 83 ± 0.937	0.166
Years practicing sport	13.75 ± 8.22	14.14 ± 8.55	0.894

Values are presented as mean ± SD. P values less than 0.05 indicating group differences are reported in bold. The data shown refer to phase I of both groups.

The flowchart related to recruitment and the final number of participating athletes can be observed in Figure 1.




Figure 1. Flowchart to recruitment.

The study was carried out in accordance with the Helsinki Declaration, approved by the local ethical committee of the Jaume I University (CD/77/2020). All participants provided written consent before the investigation. The study was registered at Clinical.Trials.gov (ID: NCT05576740).

Test protocol

Table 1 shows a summary of the protocol for the tests performed. Following the established test protocol, possible symptomatology/acute illness, medication intake and time of last intake was initially verified during the first visit. In HC users it was verified that the method of administration had been correct. The time of day of the tests, as well as previous exercise, was adapted to the work and sports calendar of the participants, ensuring that the 2 visits (contraceptive MC) or 3 visits (natural MC) were at the same time of day and with the same preconditions.

(i) Bioimpedance

Next, the sizing and bioimpedance were performed. Height was measured using a SECA 213 portable stadiometer (Seca GmbH & Co. Kg, Hamburg, Germany). To obtain the Body Mass Index (BMI), percentage of fat mass (%FM), percentage of lean body mass (%LBM), skeletal muscle mass (kg) and percentage of water (%H₂O) a bioelectrical impedance scale (Tanita BC-780MA, Tanita Corp., Tokyo, Japan) was used (31). The measurements were made following the manufacturer's guidelines. The skin and electrodes of the scale were impregnated with conductive gel before the test.

Additionally, following the recommendations for performing bioimpedance, the athlete should not have consumed any food or beverages at least 2.5 hours prior to the assessment (31).

(ii) Sensory and first pain threshold test

For the sensory and pain measurement tests, a high-voltage stimulator (DS7A, Digitimer Ltd., UK) was used (32) to deliver a series of percutaneous electrical impulses of increasing amplitude through electrodes placed in the flexor muscle of the wrist. Participants were instructed to report any sensations associated with the current, in response to the increase of power. The first sensation identified was defined as the sensory threshold (ST). The participants finished this part of the test when they detected the first electrical impulse. The intensity was then increased until the first sensation of pain was observed (34). After reporting the first painful sensation, the intensity was reduced, until the participants indicated that the pain had disappeared, and that value was noted. It was increased again until the pain reappeared, and the corresponding intensity value was recorded. The maximum value of the three readings was recorded as the first pain threshold (35). The currents were administered under a compliance of 400V, with a Pulse Duration of 2000 ms. The intensity was always increased and decreased in ranges of 0.05 mA. In the search for the sensory threshold, the current amplitude x1 was used, and to determine the first pain threshold the current amplitude x10 was used.

(iii) Blood test

The blood sample was collected from the antecubital vein as venous blood. After centrifugation, the sample was transported to the laboratory for immediate analysis. The blood sample was always collected prior to the physical tests. Serum samples were processed using the Architect c-8000 system (Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064, USA) using chemiluminescence method for the determination of LH, FSH, 17 β -Estradiol, progesterone, SHBG, and testosterone.

(iv) Warm-up and fitness level assessment tests

After this, the participants performed a standardized 5-minute stationary bike warm-up, between 75-85 rpm (Cateye EC-3200, Osaka, Japan). Subsequently, all the athletes performed a protocol of 5 exercises for the warm-up of muscle groups of legs, trunk and arms.

Subsequently, the athletes proceeded with a battery of physical tests to assess flexibility, hand grip strength, high-speed strength, and cardiorespiratory fitness. There were a total of 8 tests in the following order:

The Sit and Reach test was used to measure flexibility (36).

Maximum grip dominant hand (hand grip) (37,38) was measured with a dynamometer (Takei TKK 5101, Tokyo, Japan). The athletes were instructed to stay in a relaxed position, and after a countdown of 3 seconds they had to make the maximum possible force with their hand on the dynamometer, maintaining the maximum prehensile force for 5 seconds. Previously, the width of the dynamometer was adjusted to the comfort of each athlete.

Jump battery (39): Squat Jump with additional weight (50% body weight) (40), Squat Jump without additional weight (41), Counter Movement Jump (41), Abalakov Jump (40), Drop jump from 40 centimeters with arm swing) (40,42,43). The jump height was estimated by the flight time measured with a contact platform (Chronojump, Barcelona, Spain) (44). Before the jumps they were instructed on how to perform each of them. For Squat Jump with additional weight, the participant placed a bar over the shoulders with the corresponding weight.

Finally, the Course Navette test (45). The test was stopped by the participant's own fatigue or when for 2 consecutive times they failed to step on the line that marks the 20 meters before the test sounds. The measurement of maximum oxygen consumption ($\dot{V}O_{2max}$) was carried out. The measurement of maximum oxygen consumption ($\dot{V}O_{2max}$) was indirectly determined using the Course Navette test, following the protocol developed by Luc Léger et al (46). The predicted $\dot{V}O_{2max}$ was calculated using the formula: predicted $\dot{V}O_{2max} = 24.4 + 6 \cdot X_1$, where X_1 represents the athlete's maximal shuttle speed (km/h). Additionally, the distance covered by the athletes during the test was measured using the method described by Garcia and Secchi (47).

For these tests (excluding the Course Navette test) all participants made three attempts with a one-minute rest between each attempt. The best result obtained was recorded.

Statistical analysis

The sample size was calculated based on a previous study (48) that reported a mean VO_2 of 4.49 (SD = 0.98; IC 95% [3.911,5.069]) in Phase I and 4.52 (SD = 0.90; IC 95% [3.988,5.052]) in Phase III. Taking into account the correlation values between VO_2 ($r = .83$) obtained by Farrell et al. (49) and with a statistical power of 85%, a sample size

size of 46 subjects was estimated to detect a mean difference of 0.25 VO_2 ($ml \cdot kg^{-1} \cdot min^{-1}$) between the follicular and luteal phases.

Statistical analyses were performed using the Statistical Package for the Social Science (IBM SPSS Statistics for Windows, version 25.0, IBM Corp., Armonk, NY), and values of $p < 0.05$ were considered statistically significant. The normal distribution of variables was verified by the Shapiro-Wilk test. As the variables were not normally distributed, non-parametric statistical tests were applied. To describe the collected data, we used the mean and standard deviation for continuous variables, and frequency for categorical variables. The Friedman test was used to analyze the evolution of parameters throughout the natural MC, and the Wilcoxon test for the evolution of contraceptive MC parameters. Post-hoc comparisons were made using the Bonferroni adjustment for multiple comparisons. The Mann-Whitney U test was used to compare parameters between the two study groups. The effect size was determined using Cohen's d. A d value of 0.1 indicated a very small effect size, d (0.2) small, d (0.5) medium, d (0.8) large, d (1.2) very large, and d (2.0) huge (50,51).

Given the limited sample size and the non-normal distribution of the independent variables, the residual errors of the resulting models were inspected to ensure their normal distribution and thus the reliability of the regression models. In order to identify the predictive value of the model, the Cohen criteria to unidirectional ANOVA models. This criterion indicates that the values of R^2 below 0.10 do not give a relevant explanatory value; an R^2 between 0.10 and 0.25 indicates a dependence of the analyzed variables on the explanatory variance of the identified factors; and R^2 values greater than 0.25 allow us to affirm that the explanatory model is clinically relevant.

3. Results.

41 women (natural MC, $n=27$; contraceptive MC, $n=14$) were part of the research. After analyzing the blood tests' results, data from a total of 34 women were included in the analysis (Women with natural MC, $n=20$ and women with contraceptive MC, $n=14$). 7 women with natural MC were

excluded from the analyses for not having a progesterone greater than 16 nmol·L⁻¹ during the luteal phase (17,23). Figure 1 shows a flow chart regarding the recruitment process and inclusion of participants.

Regarding the characteristics of the participants, they are shown in Table 2. No statistically significant differences were found between the 2 study groups.

3.1. Sex hormones

Table 3 shows the levels of natural MC sex hormones in the different phases analyzed. Progesterone, estrogen, P/E ratio, FSH, LH, total testosterone and FAI levels differed between phases.

Table 3. Sex hormone levels in the natural menstrual cycle.

Measurement Natural cycle	PHASE I	P value / d de Cohen	PHASE II	P value / d de Cohen	PHASE III	P value / d de Cohen
Progesterone (nmol/L)	1.98± 1.09 (1.47 to 2.49) ^b	0.022/0.80	9.21±8.84 (5.07 to 13.35) ^c	0.005/1.66	33.89± 9.80 (29.30 to 38.48) ^a	0.001/3.28
Estrogen (pmol/L)	140.39± 84.50 (100.84 to 179.94) ^b	0.001/1.05	493.34± 326.31 (340.62 to 646.06)		519.26 ± 192.54 (429.14 to 609.38) ^a	0.001/2.05
P/E ratio	20.94±19.87 (26.84-9.59) ^b		29.07±29.52 (39.73-4.75) ^c	0.001/1.01	72.20±29.30 (94.79-50.64) ^a	0.001/2.16
FSH (mIU/mL)	6.01± 1.69 (5.21 to 6.80) ^b		5.88± 3.53 (4.22 to 7.54) ^c	0.001/0.83	2.75± 0.90 (2.32 to 3.17) ^a	0.001/1.79
LH (mIU/mL)	4.07± 1.83 (3.21 to 4.92) ^b	0.001/0.61	15.07± 18.10 (6.59 to 23.54) ^c	0.001/0.62	3.80± 2.41 (2.67 to 4.93)	
Total testosterone (nmol/L)	1.21± 0.37 (1.03 to 1.38) ^b	0.02/0.54	1.38 ± 0.41 (1.18 to 1.57) ^c	0.02/0.84	1.13 ± 0.24 (1.01 to 1.24)	
SHBG (nmol/L)	75.69 (63.41 to 87.96)		81.13 (66.32 to 95.93)		83.98 (68.12 to 99.84)	
Free Androgen Index (nmol/L)	1.68± 26.22 (1.45 to 1.91)		1.92 ± 31.63 (1.49 to 2.35) ^c	0.011/0.46	1.54 ± 33.88 (1.22 to 1.86) ^a	0.027/0.30

Values are presented as mean ± SD and 95% confidence interval. ^a Significantly different from phase I; ^b Significantly different from phase II; ^c Significantly different from phase III; P/E ratio: progesterone/estrogen ratio; Free androgen index: [(total testosterone/SHBG) ×100].

Table 4 shows the sex hormone levels of the contraceptive MC. Levels of estrogen, P/E ratio, FSH, LH, total testosterone, SHBG and FAI show significant differences between the inactive HC phase and the active phase.

Table 4. Sex hormone levels in the contraceptive menstrual cycling.

Measurement Contraceptive MC	Inactive HC phase	Active HC Phase	P value	d de Cohen
Progesterone (nmol/L)	2.22± 0.95 (1.67 to 2.77)	2.95± 1.78 (1.60 to 3.60))	0.470	0.28
Estrogen (pmol/L)	103.14± 130.53 (27.77 to 178.51)	30.05± 58.29 (-3.60 to 63.71)	0.016	0.49
P/E ratio	63.90±79.03 (18.27 to 109.54)	200.44±211.18 (78.50 to 322.37)	0.026	0.70
FSH (mIU/mL)	5.05± 3.42 (3.33 to 7.29)	1.07± 1.27 (0.34 to 1.81)	0.001	1.2
LH (mIU/mL)	2.72± 2.41 (1.33 to 4.12)	0.59± 0.02 (0.06 to 1.12)	0.003	0.8

Total testosterone (nmol/L)	1.34± 0.41(1.10 to 1.58)	1.01± 0.25(0.86 to 1.16)	0.003	1.09
SHBG (nmol/L)	217.91± 92.81 (164.32 to 271.50)	361.59± 142.64 (279.23 to 443.95)	0.002	1.51
Free Androgen Index (nmol/L)	0.84±0.76 (0.39 to 1.28)	0.36±0.24 (0.22 to 0.50)	0.005	0.60

Values are presented as mean ± SD and 95% confidence interval; P/E ratio: progesterone/estrogen ratio; Free androgen index: [(total testosterone/SHBG) ×100].

3.2. Fitness level and mc phases

Table 5 shows the variables related to the level of physical fitness of the women with a natural MC. The meters traveled in the Course Navette test show differences between phase I compared to phase II ($p = 0.005$; $d=1.15$) and phase III ($p = 0.034$; $d=0.40$). The $\dot{V}O_2\text{max}$ shows differences between phase I compared to phase II ($p = 0.004$; $d=1.45$) and between phase III ($p = 0.043$; $d=0.49$). The high-speed strength shows differences in the Abalakov jump between phase I and phase II ($p=0.001$; $d=0.71$).

Table 5. Association of the phases of the natural MC and parameters of sports performance, bioimpedance, sensory and first pain thresholds.

Measurement Natural cycle	PHASE I	P value/ d de Cohen (I vs II)	PHASE II	P value/ d de Cohen (II vs III)	PHASE III	P value/ d de Cohen (I vs III)
Body mass (kg)	63.23 ± 10.05 (58.52 to 67.94) ^c		62.64 ± 9.66 (58.11 to 67.16)		62.48 ± 9.74 (57.92 to 67.04) ^a	0.006/ 0,60
Total body water (L)	36.50 ± 5.02 (34.15 to 38.84)		36.39 ± 4.90 (34.09 to 38.68)		36.42 ± 4.66 (34.23 to 38.60)	
Body fat Percent (%)	20.61 ± 6,691 (17.48 to 23.74) ^c		20.18 ± 6,603 (17.09 to 23.27)		19.85 ± 6,583 (16.76 to 22.93) ^a	0.011/0.54
Skeletal muscle mass	27.84 ± 4.06 (25.93 to 29.73)		27.75 ± 3.9 (25.87 to 29.62)		27.82 ± 3.86 (26.01 to 29.62)	
BMI (kg·m⁻²)	23.05 ± 2.41 (21.92 to 24.18) ^{b,c}	0.003/ 1.15	22.84 ± 2.35 (21.73 to 23.94) ^a		22.79 ± 2.37 (21.67 to 23.90) ^a	0.040/0.68
Course Navette (meters)	1100 ± 332.96 (944 to 1255) ^{b,c}	0.005/1.15	1207 ± 316.91 (1058 to 1355) ^a		1176 ± 396.91 (990 to 1361) ^a	0.034 / 0.40
$\dot{V}O_2\text{max}$ (mL·kg⁻¹·min⁻¹)	41.75 ± 5.28 (39.27 to 44.22) ^{b,c}	0.004/ 1.45	43.85 ± 5.13 (41.44 to 46.25) ^a		43.25 ± 6.19 (40.35 to 46.14) ^a	0.043 / 0.49
Hand grip dominant hand (Kg)	32.15 ± 6.93 (28.90 to 35.40)		32.87 ± 7.80		33.51 ± 6.53 (30.45 to 36.56)	

			(29.22 to 36.52)	
Seat and reach (cm)	11.15 ± 7.41 (7.68 to 14.62)		11.28 ± 7.38 (7.82 to 14.74)	11.97 ± 6.70 (8.83 to 15.11)
SJ 50% additional body weight (cm)	14.08 ± 3.74 (12.33 to 15.84)		14.40 ± 3.76 (12.67 to 16.20)	14.85 ± 4.04 (12.96 to 16.74)
SJ (cm)	26.49 ± 5.19 (24.06 to 28.92)		25.97 ± 5.52 (23.39 to 28.56)	26.74 ± 5.91 (23.74 to 29.51)
CMJ (cm)	27.80 ± 5.40 (25.27 to 30.33)		27.38 ± 5.00 (27.38 to 29.73)	28.58 ± 6.10 (25.72 to 31.44)
ABK jump (cm)	30.23 ± 5.19 (29.28 to 34.63) ^b	0.001 / 0.71	29.15 ± 5.45 (27.77 to 32.77) ^a	30.21 ± 6.00 (28.47 to 34.87)
DJ 40cm (cm)	24.32 ± 6.25 (21.39 to 27.24)		25.39 ± 6.42 (22.38 to 28.40)	25.45 ± 7.72 (21.84 to 29.07)
Sensory threshold (mA)	0.64 ± 0.22 (0.53 to 0.74) ^b	0.017/0.50	0.76 ± 0.29 (0.62 to 0.89) ^a	0.75 ± 0.29 (0.61 to 0.89)
First pain threshold (mA)	1.34 ± 1.05 (0.85 to 1.83) ^{b,c}	0.027/0.40	1.69 ± 1.60 (0.94 to 2.44) ^a	1.59 ± 1.31 (0.97 to 2.20) ^a

Values are presented as mean ± SD and 95% confidence interval. ^aSignificantly different from phase I; ^bSignificantly different from phase II; ^cSignificantly different from phase III; Only p-values and Cohen's d values p<0.05 are presented. SJ: Squat jump, CMJ: Counter movement jump, ABK jump: Abalakov jump; DJ: Drop Jump.

Table 6 shows the variables related to the level of physical fitness of the women with an contraceptive MC. The meters traveled in the Course Navette test (p=0.040;d=0.59), flexibility (p=0.041;d=0.22) and high-speed strength by SJ with 50% additional weight (p=0.009;d=0.40), differed between the inactive phase and active phase of the contraceptive menstrual cycling.

Table 6. Association of the phases of the contraceptive MC and parameters of sports performance, bioimpedance, sensory and first pain thresholds.

Measurement Contraceptive menstrual cycling	Inactive HC phase	Active HC Phase	P value
Body mass (kg)	59.75 ± 7.67 (55.32 to 64.18)	59.02 ± 7.68 (54.58 to 63.45)	0.027/0.87
Total body water (L)	33.49 ± 2.70 (31.93 to 35.05)	33.56 ± 2.54 (32.08 to 35.02)	
Body fat Percent (%)	22.64 ± 7.88 (18.08 to 27.19)	21.54 ± 7.96 (16.94 to 26.14)	0.014/0.76

Skeletal muscle mass	25.34 ± 2.23 (24.04 to 26.62)	25.39 ± 2.10 (24.17 to 26.60)	
BMI (kg·m⁻²)	22.79 ± 3.08 (21.00 to 24.56)	22.49 ± 3.04 (20.73 to 24.25)	0.017/0.66
Course Navette (meters)	1110.00 ± 305.81 (933 to 1285)	1185.71 ± 307.58 (1008 to 1363)	0.040/0.59
$\dot{V}O_2\text{max}$ (mL·kg⁻¹·min⁻¹)	42.02 ± 4.53 (39.41 to 44.64)	42.60 ± 6.34 (38.93 to 46.26)	
Hand grip hand dominant (kg)	27.82 ± 3.32 (25.89 to 29.74)	29.31 ± 3.89 (27.06 to 31.56)	
Seat and reach (cm)	10.95 ± 6.68 (7.09 to 14.81)	11.51 ± 7.68 (7.07 to 15.95)	0.041/0.22
SJ WITH 50% additional body weight (cms)	12.15 ± 5.84 (8.77 to 15.52)	13.48 ± 5.85 (10.10 to 16.86)	0.009/0.40
SJ (cms)	23.26 ± 6.81 (19.32 to 27.19)	23.80 ± 7.29 (19.58 to 28.01)	
CMJ (cms)	24.20 ± 7.10 (20.10 to 28.31)	25.07 ± 7.83 (20.55 to 29.59)	
ABK jump (cms)	27.71 ± 8.03 (23.07 to 32.35)	28.52 ± 8.05 (23.88 to 33.17)	
DJ (cms)	23.42 ± 9.87 (17.17 to 29.12)	22.02 ± 8.77 (16.95 to 27.09)	
Sensory threshold (mA)	0.57 ± 0.26 (0.42 to 0.73)	0.62 ± 0.19 (0.51 to 0.73)	
First pain threshold (mA)	1.43 ± 0.98 (0.86 to 2.00)	1.67 ± 1.14 (1.01 to 2.33)	

Values are presented as mean ± SD and 95% confidence interval. Only p-values and Cohen's d values p<0.05 are presented. SJ: Squat jump, CMJ: Counter movement jump, ABK jump: Abalakov jump; DJ: Drop Jump.

3.3. Body composition

Table 5 shows the information related to the body composition of natural MC. The weight differed between phase I and phase III (p=0.006; d=0.60), the same occurred with the percentage of fat mass (p=0.011; d=0.54). The BMI showed variation between phase I and II (p=0.003; d=1.15) and between phase I and III (p=0.040; d=0.68).

Table 6 shows the information related to the body composition of the contraceptive MC. As in natural MC, the variables that differ between the two key phases of contraceptive MC are weight (p=0.027; d=0.87), BMI (p=0.017; d=0.66) and percentage of fat mass (p=0.014; d=0.76).

3.4. Sensory threshold and pain threshold

Regarding natural MC, Table 5 shows information related to the sensory and first pain thresholds. In the first pain threshold, there are significant differences between phase I and II (p = 0.027; d=0.40) and between phase I and III (p=0.011; d=0.31), however these differences are not evident in contraceptive MC (Table 6). Significant differences were also found in sensory threshold in the natural MC between phase I and II (p=0.017; d=0.50).

3.4.1. Multiple regression analysis

The results of the multiple regression analysis are as follows, in Table 7. When performing the multiple linear regression analysis using $\dot{V}O_2\text{max}$ as a dependent variable, we found that in phase I of athletes with natural MC, the first pain threshold justifies 31.9% of the variance, which we consider as clinically relative if we follow Cohen's criteria (50,51).

Table 7. Result of the multiple regression analysis.

Model	R ² Adjusted	Standardized Coefficients Beta	Standard Error	F (p)
Dependent Variable: $\dot{V}O_{2max}$ Covariates: First pain threshold.	0.319	0.595	4.3619	9.885 (0.006)

4. Discussion.

The objective of the present study was to observe whether the MC, both natural MC and contraceptive cycling, causes variations related to the level of physical fitness, body composition, pain and sensitivity. The latest recommendations of the literature on how to properly verify the phases of the MC are followed and the results of women who did not obtain a minimum value of progesterone to consider the natural MC as ovulatory are eliminated from the analysis (52). Therefore, it is expected that the following lines will be satisfactory to draw conclusions about the MC and its relationship with physical fitness of athletes.

Influence of natural MC on cardiorespiratory fitness

The main finding of the present study was the variation of $\dot{V}O_{2max}$ and the meters covered in the Course Navette test between the phases of the natural MC. Although some studies have concluded that no changes have been found in $\dot{V}O_{2max}$ related to MC (11,53) this may be due to a low number of participants (n <10), the potential inclusion of deficient luteal phases due to the lack of hormonal blood concentration determination, or the monitoring of <=2 phases of MC. In this research, both $\dot{V}O_{2max}$ and the meters covered in the Course Navette test were significantly lower in phase I compared to phases II and III. In line with our research, Barba-Moreno et al. (54) observed a lower $\dot{V}O_{2max}$ in phase I. In the present study, the cardiorespiratory fitness related to the $\dot{V}O_{2max}$, varies depending on the phase of the cycle that the athlete is in, obtaining differences of up to 2 mL·kg⁻¹·min⁻¹. It can be said that women have a higher cardiorespiratory fitness in the last two phases of the cycle.

The variation in $\dot{V}O_{2max}$ could be attributed to the significant changes found in sex hormone levels between phases. In women, estrogens have been positively linked to physical fitness (7). In phase I (140.39 pmol/L), estrogens are significantly lower than phase II and III (493.34 and 519.26 pmol/L) (p<0.05), so it could justify the variation of $\dot{V}O_{2max}$. Estrogens cause anabolic effects, increasing glycogen uptake and storage (55,56). Moreover, they have neuroexcitatory effects, enhancing voluntary activation and decreasing inhibition, affecting cardiorespiratory fitness of maximum or submaximal intensity (57). In addition to estrogen, testosterone has a powerful effect on muscle tissue (58) and has been attributed a protective role against severe fatigue (59) and this variable is significantly higher in phase II compared to other phases. Testosterone levels followed normative serum androgen values in elite female athletes determined by Stéphane Bermon et al. (18).

Another important discovery was that weight, BMI and fat percentage were higher in phase I of natural MC compared to phase III. The percentage of water and muscle mass did not change, suggesting that weight difference is associated with the percentage of fat. Coinciding with this observation, the $\dot{V}O_{2max}$ was lower in phase I compared to phase III. It could be said that the achievement of the $\dot{V}O_{2max}$ is related to the weight and % of fat of the athlete, and these were greater in phase I, as the women did not reach the maximum levels as achieved in the rest of the phases. $\dot{V}O_{2max}$ is expressed in mL·kg⁻¹·min⁻¹ so it makes sense that changes in body weight can influence it (15). In line with our results, Martínez-Navarro et al. (60) confirmed that women's % fat influences the $\dot{V}O_{2max}$ variable.

Influence of natural MC on high-speed strength, hand grip strength and flexibility

Regarding the level of hand grip strength, in line with various studies, the hand grip of dominant hand does not differ between the phases of the natural MC (61,62).

Most tests related to lower body high-speed strength were not significant, in line with a study that analyzed the CMJ in soccer players (10). However, this study only studied this variable in phase I and III. As already indicated in their study Thompson et al. (61) it is important to take into account the late follicular phase (phase II in this research) when estrogen is high and progesterone low, where several studies have confirmed that there is a decrease in musculotendinous stiffness of the lower extremities (63) and an increase in muscle extensibility and joint laxity (64), being detrimental to the jump, since flexible musculature reduces the development of high-speed strength. Thompson et al. (61) stated that the faster and more explosive aspects of muscle performance could be influenced by MC hormones. In our study, the height in centimeters for the Abalakov jump was significantly shorter during phase II than during phase I. No other jumps showed significant differences, on the contrary, studies that analyze the CMJ jump in women who perform physical activity recreationally (61,62) have found differences between the phases. These controversial results could be due to the difference in the baseline physical fitness level of the participants, since in studies that do not show differences, they are women athletes. This must be due to the technical component of the Abalakov jump, as the arms are used, unlike in the other jumps, and is most frequently used among female athletes.

Regarding flexibility, no significant differences were reported. However, Campa et al. (65) did find differences between Phase I and Phase II of the menstrual cycle. The discrepancies in findings could be attributed to differences in verifying the phases or variations in sample characteristics. Our results, where flexibility remains unchanged, align with the findings on high-speed strength in our study. If flexibility does not vary, muscle-tendon stiffness and muscle extensibility would remain constant, not affecting the results of the jumps. Therefore, it is believed that estrogen fluctuation is not capable of significantly influencing flexibility. Similarly, it is believed that estrogens do not have a significant impact on high-speed strength and hand grip strength. As evidenced by the measurement of estrogen in this research, high-speed strength and hand grip strength levels could be expected to be higher in phase II and III compared to phase I. However, the finding regarding these variables make us reject the hypothesis that estrogens increase the level of high-speed strength, since this is when these are lower. This finding is consistent with the study conducted by Tine Vrist Dam et al. (62), who also rejected this hypothesis. It is thought that the fluctuation of estrogen associated with the menstrual cycle does not cause substantial changes in high-speed and hand grip strength.

Influence of natural MC on the pain and sensory thresholds

Another important finding was related to sensory threshold and first pain threshold. M. Sambanis et al. (66) in their research confirmed that female athletes felt increased fatigue and weakness during menstruation (phase I). In our study, the sensory threshold was lower in phase I compared to phase II, and the first pain threshold was lower in phase I compared to phases II y III, and consequently, we could affirm that women have a greater sensitivity and a lower tolerance to pain in the first phase of the cycle. We consider that this finding could be related to the hormonal fluctuations experienced during the MC. Therefore, the decrease in this threshold could be related to the values of $\dot{V}O_2\text{max}$. First pain threshold was significantly higher in phase II and III, so they could help female athletes achieve higher levels of cardiorespiratory fitness. These results are reaffirmed by the association found through regression analyses between $\dot{V}O_2\text{max}$ and first pain threshold in phase I, explaining 31.9 % of the variance. Romero-Parra, et al. (67) confirmed that women perceived muscle soreness more severely before exercise performed in phase I, when estrogen concentrations are relatively low, which may affect women's predisposition to strenuous exercise during this phase.

The methodological approach used in this research, with the incorporation of the measurement of pain and sensitivity related to the phases of MC is novel in the scientific literature, since no similar work has been found, where a combined measurement of both variables occurs. With the results obtained, we consider it pertinent to open new lines of research in this direction.

Influence of contraceptive menstrual cycling phases on the level of cardiorespiratory fitness, high-speed strength, hand grip strength and flexibility

In our research, significant differences have been found between some study variables for contraceptive MC. Conversely, a systematic review on the influence of the contraceptive MC on performance concluded that there were no differences between the phases, but 83% of its articles were rated as moderate, low or very low methodological quality (3). In this study, differences have been found on the meters traveled in the Course Navette test. As in the natural MC, the weight and % of fat differs significantly between phases and may be associated with the variation of meters reached in the Course Navette test, since women travel more meters when the % of fat is lower, and although the change is small, it is considered significant in athletes. Unlike in the contraceptive MC, there were not much difference in the $\dot{V}O_{2max}$, only on the meters traveled. Similarly, Barba-Moreno et al. (54) they also found no difference between maximal oxygen consumption. In addition to the above explanation, the fact that the $\dot{V}O_{2max}$ fluctuates, is associated with the high level of estrogens, and although these vary significantly between the inactive phase and the active phase, they are not high enough levels to cause changes in this variable. Therefore, we can confirm that in our study the hormonal fluctuation related to the contraceptive MC does not cause substantial changes in the cardiorespiratory fitness.

As far as the measurement of the level of force is concerned, the hand grip does not differ in this type of cycle (61,62) either. Regarding the jumps, there are differences in the jump squat jump with additional weight. It is thought that the significant variation in weight and % of fat between phases has contributed to the athletes performing better in the active phase, compared to the inactive contraceptive phase where the weight was higher. This jump involves moving 50% of your body weight, therefore, in addition to decreasing body weight in this phase, the additional load is also decreased, which may be the reason for the increase of centimeters in this jump. Regarding flexibility, despite statistically significant differences between both phases, the p-value and effect size are small ($p=0.041$; $d=0.22$), indicating that this association requires further investigation.

STUDY LIMITATIONS

Although this research consisted of 41 participants (a total of 123 assessments), it is considered more appropriate to increase the sample size following the recommendations of the literature (23). In the future, the comparison between the study groups could be made, in order to clarify whether or not there is a difference in the physical fitness between both types of cycles. In addition, future research to study in women with deficient luteal phases and their characteristics related to sports performance would be useful.

Another limitation found in the study is the complexity involved in monitoring this type of assessment atletas entre el nivel II y III de McKay (30). It is an imposition, to make the visits in the planned timetable, depending on the woman's own MC while also adapting to her sport routine.

5. Conclusions

Athletes classified between levels II and III of McKay's classification, who have a natural menstrual cycle, experience changes in $\dot{V}O_{2max}$ depending on the phase of the MC they are in. This variation is thought to be influenced by fluctuations in sex hormones, body weight, % fat, sensory and first pain thresholds associated with the MC. The pain and sensory thresholds fluctuate between the first two phases and seems to affect the $\dot{V}O_{2max}$. High-speed Strength also undergoes changes according to the phases of the MC, but it should be studied more deeply in athletes nivel II y III de McKay.

Athletes with contraceptive MC experience differences in the meters traveled in the Course Navette test and in the Squat jump with additional weight and it seems to be related to the fluctuation of body weight that also occurs in this type of cycles.

Based on the results obtained, this article recommends adapting training and competitions for athletes classified as level II and III according to McKay's classification, as cardiorespiratory fitness varies during the natural MC.

In athletes with contraceptive MC, there is no variation in the sensory and first pain thresholds or in the $\dot{V}O_2\text{max}$. Neither do the women benefit from the increase in the cardiorespiratory fitness in phases II and III found in women of natural MC, so the use of HC is not harmless with respect to their physical condition.

It highlights the need for the correct verification of the phases of the MC by blood measurement of sex hormones, so that the correct scientific conclusions can be drawn.

Funding: This research received no external funding

Institutional Review Board Statement: The study was carried out in accordance with the Helsinki Declaration, approved by the local ethical committee of the Jaume I University (CD/77/2020). The study was registered at Clinical.Trials.gov (ID: NCT05576740).

Informed Consent Statement: All participants provided written consent before the investigation.

Acknowledgments: To all the women who have participated in the study, for their time, dedication, and motivation. To Chair of Physical Activity and Oncology (CAFO) and Endavant Villarreal CF Chair of Sport of Jaume I University; to sport and women chair of the University of Valencia. To all the team that has been part of this project.

Conflicts of Interest: The authors state that this research was carried out without commercial or financial relationships that could pose a conflict of interest. The results are shown truthfully and clearly, without any falsification or manipulation.

References

1. Oosthuysen T, Bosch AN. The effect of the menstrual cycle on exercise metabolism: Implications for exercise performance in eumenorrhoeic women. *Sport Med.* 2010;40(3):207–27.
2. National Strength & Conditioning Association. *Essentials of Strength Training and Conditioning*. 4th ed. Haff GG, Triplett NT, editors. 2016.
3. Elliott-Sale KJ, McNulty KL, Ansdell P, Goodall S, Hicks KM, Thomas K, et al. The Effects of Oral Contraceptives on Exercise Performance in Women: A Systematic Review and Meta-analysis. *Sport Med.* 2020;50(10):1785–812.
4. McNulty KL, Elliott-Sale KJ, Dolan E, Swinton PA, Ansdell P, Goodall S, et al. The Effects of Menstrual Cycle Phase on Exercise Performance in Eumenorrhoeic Women: A Systematic Review and Meta-Analysis. *Sport Med [Internet]*. 2020;50(10):1813–27. Available from: <https://doi.org/10.1007/s40279-020-01319-3>
5. Conde E. The reconciliation of sporting life and training of top-level sportsmen and women in Spain: A quantitative overview. 2013;447.
6. Findlay RJ, MacRae EHR, Whyte IY, Easton C, Forrest LJ. How the menstrual cycle and menstruation affect sporting performance: Experiences and perceptions of elite female rugby players. *Br J Sports Med.* 2020;54(18):1108–13.
7. Ansdell P, Brownstein CG, Skarabot J, Hicks KM, Simoes DCM, Thomas K, et al. Menstrual cycle-associated modulations in neuromuscular function and fatigability of the knee extensors in eumenorrhoeic women. *J Appl Physiol.* 2019;126(6):1701–12.
8. Hackney AC. *Sex Hormones, Exercise and Women*. 1st ed. Sex Hormones, Exercise and Women. 2017. 315 p.
9. Lemmer JT, Ivey FM, Ryan AS, Martel GF, Hurlbut DE, Metter JE, et al. Effect of strength training on resting metabolic rate and physical activity: Age and gender comparisons. *Med Sci Sports Exerc.* 2001;33(4):532–41.
10. Julian R, Hecksteden A, Fullagar HHK, Meyer T. The effects of menstrual cycle phase on physical performance in female soccer players. *PLoS One.* 2017 Mar;12(3).
11. Forsyth J, Reilly T. The effect of menstrual cycle on 2000-m rowing ergometry performance. *Eur J Sport Sci.* 2008;8(6):351–7.
12. Fazil KN, Fatyh K, Guleda B, Murat T, Yakup P, Fulya E. Some Performance Parameter Changes During Menstrual Cycle Periods of Athletes and Non-Athletes. *Ovidius Univ Ann Ser Phys Educ Sport Mov Heal [Internet]*. 2010;10(1):46–9. Available from: <http://search.ebscohost.com/login.aspx?direct=true&db=s3h&AN=53995267&lang=pt-br&site=ehost-live>

13. Štefanovský M, Péterová A, Vanderka M, Lengvarský L. Influence of selected phases of the menstrual cycle on performance in special judo fitness test and wingate test. *Acta Gymnica*. 2016;46(3):136–42.
14. De Souza MJ, Miller BE, Loucks AB, Luciano AA, Pescatello LS, Campbell CG, et al. High frequency of luteal phase deficiency and anovulation in recreational women runners: Blunted elevation in follicle-stimulating hormone observed during luteal-follicular transition. *J Clin Endocrinol Metab*. 1998;83(12):4220–32.
15. Janse De Jonge XAK. Effects of the menstrual cycle on exercise performance. *Sport Med*. 2003;33(11):833–51.
16. Schaumberg MA, Jenkins DG, Janse de Jonge XAK, Emmerton LM, Skinner TL. Three-step method for menstrual and oral contraceptive cycle verification. *J Sci Med Sport [Internet]*. 2017;20(11):965–9. Available from: <http://dx.doi.org/10.1016/j.jsams.2016.08.013>
17. de Jonge XJ, Thompson B, Han A. Methodological Recommendations for Menstrual Cycle Research in Sports and Exercise. *Med Sci Sport Exerc*. 2019;1.
18. Berman S, Garnier PY, Hirschberg AL, Robinson N, Giraud S, Nicoli R, et al. Serum androgen levels in elite female athletes. *J Clin Endocrinol Metab*. 2014;99(11):4328–35.
19. De Crée C. Sex steroid metabolism and menstrual irregularities in the exercising female. *Sport Med*. 1998;25(6):369–406.
20. Schaumberg MA, Jenkins DG, Janse De Jonge XAK, Emmerton LM, Skinner TL. Oral contraceptive use dampens physiological adaptations to sprint interval training. *Med Sci Sports Exerc*. 2017;49(4):717–27.
21. Burrows M, Bird S. The physiology of the highly trained female endurance runner. *Sport Med*. 2000;30(4):281–300.
22. Keller MF, Harrison ML, Lalande S. Impact of Menstrual Blood Loss and Oral Contraceptive Use on Oxygen-carrying Capacity. *Med Sci Sport Exerc*. 2019;(December):1.
23. Elliott-Sale KJ, Minahan CL, de Jonge XAKJ, Ackerman KE, Sipilä S, Constantini NW, et al. Methodological Considerations for Studies in Sport and Exercise Science with Women as Participants: A Working Guide for Standards of Practice for Research on Women. *Sport Med [Internet]*. 2021;51(5):843–61. Available from: <https://doi.org/10.1007/s40279-021-01435-8>
24. Russell AM, Benton D, Kingsley M. Period Prevalence and Perceived Side Effects of Hormonal Contraceptive Use and the Menstrual Cycle in Elite Athletes. *Int J*. 2011;
25. Reilly T. The Menstrual Cycle and Human Performance : An Overview The Menstrual Cycle and Human Performance : 2010;1016(200002):37–41.
26. Spona J, Elstein M, Feichtinger W, Sullivan H, Lüdicke F, Müller U, et al. Shorter pill-free interval in combined oral contraceptives decreases follicular development. *Contraception*. 1996;54(2):71–7.
27. Blode H, Kowal K, Roth K, Reif S. Pharmacokinetics of drospirenone and ethinylestradiol in Caucasian and Japanese women. *Eur J Contracept Reprod Heal Care*. 2012;17(4):284–97.
28. Endrikat J, Blode H, Gerlinger C, Rosenbaum P, Kuhn W. A pharmacokinetic study with a low-dose oral contraceptive containing 20 µg ethinylestradiol plus 100 µg levonorgestrel. *Eur J Contracept Reprod Heal Care*. 2002;7(2):79–90.
29. Sociedad Española de Ginecología. Combined Oral, Transdermal and Vaginal Hormonal Contraception. 2006;(28036):1–20.
30. McKay AKA, Stellingwerff T, Smith ES, Martin DT, Mujika I, Goosey-Tolfrey VL, et al. Defining Training and Performance Caliber: A Participant Classification Framework. *Int J Sports Physiol Perform*. 2022;17(2):317–31.
31. Byrne NM, Hills AP, Hunter GR, Weinsier RL, Schutz Y. Metabolic equivalent: One size does not fit all. *J Appl Physiol*. 2005;99(3):1112–9.
32. Digitimer. Digitimer Operator's Manual. 2013.
33. Current DC, Voltage H. Digitimer. 2014;510.
34. de Brito Barbosa M, de Oliveira Guirro EC, Nunes FR. Evaluation of sensitivity, motor and pain thresholds across the menstrual cycle through medium-frequency transcutaneous electrical nerve stimulation. *Clinics [Internet]*. 2013;68(7):901–8. Available from: [http://dx.doi.org/10.6061/clinics/2013\(07\)03](http://dx.doi.org/10.6061/clinics/2013(07)03)
35. Giamberardino MA, Berkley KJ, Iezzi S, De Bigontina P, Vecchiet L. Pain threshold variations in somatic wall tissues as a function of menstrual cycle, segmental site and tissue depth in non-dysmenorrheic women, dysmenorrheic women and men. *Pain*. 1997;71(2):187–97.
36. López-Miñarro PÁ, Vaquero-Cristóbal R, Muyor JM, Espejo-Antúnez L. Criterion-related validity of sit-and-reach test as a measure of hamstring extensibility in older women. *Nutr Hosp*. 2015;32(1):312–7.
37. Nikolaidis PT, Rosemann T, Knechtle B. Force-velocity characteristics, muscle strength, and flexibility in female recreational marathon runners. *Front Physiol*. 2018;9(NOV):1–8.
38. Ruiz JR, España Romero V, Castro Piñero J, Artero EG, Ortega FB, Cuenca García M, et al. alpha-fitness battery: Field test for the assessment of health-related physical fitness in children and adolescents. *Nutr Hosp*. 2011;26(6):1210–4.

39. National Strength & Conditioning Association. High-speed strength with a jump battery. In: Haff GG, Triplett NT, editors. *Essentials of Strength Training and Conditioning*. 4th ed. 2016.
40. Centeno Prada RA. REFERENCE VALUES FOR JUMPS ON A DYNAMOMETRIC PLATFORM IN A POPULATION OF ANDALUSIAN SPORTSMEN AND WOMEN. Universidad Pablo de Olavide; 2013.
41. De Blas X, Padullés JM, Del Amo JLL, Guerra-Balic M. Creación y validación de Chronojump-Boscosystem: un instrumento libre para la medición de saltos verticales. *RICYDE Rev Int Ciencias del Deport*. 2012;8(30):334–56.
42. de Blas X. Chronojump-Boscosystem project. Free software tool for the kinematic study of vertical jumping: time measurement, markerless bending angle detection and percentile tables. TDX (Tesis Dr en Xarxa) [Internet]. 2012; Available from: <http://www.tdx.cat/handle/10803/83302>
43. Xu J, Turner A, Comfort P, Harry JR, McMahon JJ, Chavda S, et al. A Systematic Review of the Different Calculation Methods for Measuring Jump Height During the Countermovement and Drop Jump Tests. *Sport Med*. 2023;(0123456789).
44. de Blas Foix X, Padull X. Manual de Chronojump. 2021;1–116. Available from: http://creativecommons.org/licenses/by-sa/3.0/deed.esLaúltimaversióndeestdocumentoseencuentraenlaúltimaversióndeChronojumpyaquí:http://www.chronojump.org/documents_es.html
45. Léger LA, Lambert J. A maximal multistage 20-m shuttle run test to predict VO₂ max. *Eur J Appl Physiol Occup Physiol*. 1982;49(1):1–12.
46. Léger LA, Mercier D, Gadoury C, Lambert J. The multistage 20 metre shuttle run test for aerobic fitness. *J Sports Sci*. 1988;6(2):93–101.
47. García GC, Secchi JD. 20-metre test course navette with one-minute stages. An original idea that has been around for 30 years. *Apunt Sport Med* [Internet]. 2014;49(183):93–103. Available from: <https://www.apunts.org/es-test-course-navette-20metros-con-articulo-X0213371714492019>
48. Dokumacı B, Hazır T. Effects of the Menstrual Cycle on Running Economy: Oxygen Cost Versus Caloric Cost. *Res Q Exerc Sport* [Internet]. 2019;90(3):318–26. Available from: <https://doi.org/10.1080/02701367.2019.1599800>
49. Farrel PA, Wilmore JH, Coyle EF, Billin JE, Costill DL. Plasma lactate accumulation and distance running performance. *Med Sci Sports Exerc*. 1979;25(10):1091–7.
50. Sawilowsky SS. Very large and huge effect sizes. *J Mod Appl Stat Methods*. 2009;8(2):597–9.
51. COHEN, J. The analysis of variance and covariance. *Stat Power Anal Behav Sci*. 1988;
52. de Jonge XJ, Thompson B, Ahreum HAN. Methodological Recommendations for Menstrual Cycle Research in Sports and Exercise. *Med Sci Sports Exerc*. 2019;51(12):2610–7.
53. Vaiksaar S, Jürimäe J, Mäestu J, Purge P, Kalytka S, Shakhlina L, et al. No Effect of Menstrual Cycle Phase and Oral Contraceptive Use on Endurance Performance in Rowers. *J Strength Cond Res*. 2011 Jun;25(6):1571–8.
54. Barba-Moreno L, Cupeiro R, Romero-Parra N, De Jonge XAKJ, Peinado AB. Cardiorespiratory Responses to Endurance Exercise Over the Menstrual Cycle and With Oral Contraceptive Use. *J Strength Cond Res*. 2022;36(2):392–9.
55. Baltgalvis KA, Greising SM, Warren GL, Lowe DA. Estrogen regulates estrogen receptors and antioxidant gene expression in mouse skeletal muscle. *PLoS One*. 2010;5(4).
56. Lowe DA, Baltgalvis KA, Greising SM. Mechanisms behind Estrogens' Beneficial Effect on Muscle Strength in Females. *Exerc Sport Sci Rev*. 2011;38(2):61–7.
57. Isacco L, Boisseau N. Sex Hormones and Substrate Metabolism During Endurance Exercise. In: *Sex Hormones, Exercise and Women*. Springer I. 2017. p. 35–58.
58. Vingren JL, Kraemer WJ, Ratamess NA, Anderson JM, Volek JS, Maresh CM. Testosterone physiology in resistance exercise and training: The up-stream regulatory elements. Vol. 40, *Sports Medicine*. Springer; 2010. p. 1037–53.
59. Collado-Boira E, Balaño P, Boldó-Roda A, Martínez-Navarro I, Hernando B, Recacha-Ponce P, et al. Influence of female sex hormones on ultra-running performance and post-race recovery: Role of testosterone. *Int J Environ Res Public Health*. 2021;18(19).
60. Martínez-Navarro I, Montoya-Vieco A, Collado E, Hernando B, Hernando C. Ultra Trail Performance is Differently Predicted by Endurance Variables in Men and Women. *Int J Sports Med*. 2022;43(7):600–7.
61. Thompson BM, Drover KB, Stellmaker RJ, Sculley D V, Janse de Jonge XAK. The effect of the menstrual cycle and oral contraceptive cycle on muscle performance and perceptual measures. *Int J Environ Res Public Health*. 2021;18(20).
62. Dam TV, Dalgaard LB, Sevdalis V, Bibby BM, Janse De Jonge X, Gravholt CH, et al. Muscle Performance during the Menstrual Cycle Correlates with Psychological Well-Being, but Not Fluctuations in Sex Hormones. *Med Sci Sports Exerc*. 2022;54(10):1678–89.

63. Eiling E, Bryant AL, Petersen W, Murphy A, Hohmann E. Effects of menstrual-cycle hormone fluctuations on musculotendinous stiffness and knee joint laxity. *Knee Surgery, Sport Traumatol Arthrosc.* 2007;15(2):126–32.
64. Bell DR, Blackburn JT, Hackney AC, Marshall SW, Beutler AI, Padua DA. Hamstring Stiffness and Knee Laxity Across the Menstrual Cycle in Females with ACL Reconstruction. *Med Sci Sport Exerc.* 2011;43(5):805.
65. Campa F, Micheli ML, Pompignoli M, Cannataro R, Gulisano M, Toselli S, et al. The Influence of Menstrual Cycle on Bioimpedance Vector Patterns, Performance, and Flexibility in Elite Soccer Players. *Int J Sports Physiol Perform.* 2022;17(1):58–66.
66. Sambanis M, Kofotolis N, Kalogeropoulou E, Noussios G, Sambanis P, Kalogeropoulos J. A study of the effects on the ovarian cycle of athletic training in different sports. *J Sports Med Phys Fitness.* 2003;43(3):398–403.
67. Romero-Parra N, Alfaro-Magallanes VM, Rael B, Cupeiro R, Rojo-Tirado MA, Benito PJ, et al. Indirect markers of muscle damage throughout the menstrual cycle. *Int J Sports Physiol Perform.* 2021;16(2):190–8.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.